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Abstract: The burden of neoplastic diseases is widely recognized as a severe cause of mortality. The clinical
inadequacy of most anticancer therapeutics urgently prompted intense drug discovery e↵orts toward
the identification of new chemical entities endowed with a potent and safe antitumor profile. In this
scenario, targeting cancer cells apoptosis machinery has emerged as a relevant strategy, useful for
tackling the emergence of drug resistance. On this basis, a small library of naturally inspired hybrid
molecules was obtained by combining, through a click chemistry approach, “privileged” synthons
such as curcumin sca↵old and 1,2,3-triazole building block. Compound 1, bearing a para-fluoro phenyl
moiety, showed low-micromolar potency against T acute lymphoblastic leukemia cell growth. More
in-depth biologic studies demonstrated, for this analog, cell death-inducing properties associated with
its capability to simultaneously activate both the receptor and the mitochondrial apoptosis cascades.
This peculiar behavior o↵ers promises for achieving an expanded anticancer e↵ect, namely intense
cytotoxic response coupled with reduced predisposition of chemoresistance insurgence. Altogether,
this study allowed the identification of compound 1 as a lead compound worth to be progressed as
an anticancer drug candidate.
Keywords: apoptosis; cell cycle; cell death; click chemistry; curcumin; flow cytometry; fluorine;
privileged structure; triazole
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1. Introduction
Cancer is expected to become, in every country of the world in the 21st century, the leading
cause of death along with a remarkable obstacle for the life expectancy increasing [1]. It ranks as one
of the principal life-threatening maladies. Among conventional cancer treatments, chemotherapy
is one of the most significant approaches, but severe unwanted e↵ects, namely drug toxicity and
chemoresistance, cause a reduction in both clinical outcome and long-term survival rates. Despite
decades of research, e↵ective therapeutic interventions for several neoplastic diseases still remain
elusive and the identification of new molecules endowed with a potent and safe antitumor e↵ect is an
urgent need.
The induction of apoptosis represents a common mechanism through which several therapeutics
influence cancer cell death. Apoptosis is a very complex cellular phenomenon that can be triggered by
caspases activation by two diverse, but overlapping pathways, the intrinsic and the extrinsic one [2].
The intrinsic pathway, also known as mitochondrial or stress or apoptosis, initiates in response to
di↵erent stresses, such as microtubule-targeting and DNA-damaging agents and oncogenes activation.
It is characterized by disruption of the mitochondrial membrane, as a consequence of the liberation of
apoptogenic factors, with cell membrane electrochemical gradient disturbance. In contrast, the extrinsic
death receptor pathway originates upon specific interactions between protein ligands, such as tumor
necrosis factor (TNF) and FAS ligand, and their specific death receptor, followed by activation of
caspase-8. Both routes converge in the activation of common downstream e↵ector caspases (caspase-3,
-6 and -7) leading to apoptosis execution [3].
The aptitude of malignant cells to evade apoptosis is a widely recognized hallmark also involved
in the emergence of drug resistance, so that, targeting apoptosis has emerged as a valuable antitumor
therapeutic strategy [4]. In particular, the capability of an anticancer therapeutic to activate both the
receptor and the mitochondrial apoptosis cascades is, on two grounds, a greatly desired e↵ect. On one
hand, the simultaneous activation of both pathways promotes a more intense cytotoxic response,
if compared to the activation of just one of them. On the other, very often, mutations in cancer cells
make them unable to deliver one or the other pathway [3]. Indeed, apoptosis inducers o↵er promises
for achieving, in both normal and malignant cells, a decreased toxicity coupled with an improved
therapeutic outcome [5,6].
The anticancer potential of natural products (NPs) has attracted considerable attention in both
industry and academia. Many screening programs proved to be particularly fruitful for the identification
of lead molecules and promising sca↵olds for drug discovery purposes, as documented by the current
number of drugs based on NPs in clinical trials or available on the market [7,8]. In particular, compound
collections based on or inspired by NP structures are expected to be enriched in bioactivity, modulating
multiple biologic processes. Among NPs, the class of molecules bearing an ↵, -unsaturated carbonyl
function, a well-known Michael acceptor system, has been extensively studied and exploited due to
the distinctive capability of interacting with nucleophile sites, namely cysteine and lysine residues,
of di↵erent target proteins [9].
Curcumin (Figure 1), the main bioactive component isolated from the rhizome of Curcuma longa,
is one of the most intensely studied phytochemical. Its broad spectrum of beneficial biologic properties
including anti-inflammatory, antiproliferative, and antioxidant proved to be particularly suitable for
treating complex multifactorial diseases, including cancer [10]. The antitumor e↵ect of curcumin is the
consequence of the modulation of a large variety of signaling pathways, likely due to the electrophilic
nature of its ↵, -unsaturated carbonyl function. For instance, the induction of caspases, principally
caspase-3 and -8, endoplasmic reticulum and mitochondrial stress pathways, results in a pro-apoptotic
outcome [11].
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Figure 1. Chemical structure of curcumin and design strategy for obtaining analogs 1–6. 
In spite of the notably favorable antitumor profile, several drawbacks have been reported for 
curcumin among which poor chemical stability and aqueous solubility that negatively affect its 
bioavailability and cut the therapeutic window [12]. 
Curcumin, together with a large number of bioactive NPs, such as epigallocatechin gallate, 
quinone and rifampicin, has recently been referred to as frequently hitter or pan-assay interfering 
compound (PAIN) [13,14]. However, a large body of evidence supported that compound reactivity 
may be strictly related to the structural environment. Thus, derivatives properly designed based on 
PAIN-based synthons would perform as discriminating bioactive agents rather than reactive 
chemicals [15,16]. Extensive medicinal chemistry efforts have furnished support to this issue with the 
identification of a large variety of successful curcumin-related molecules, obtained upon appropriate 
modifications of its basic framework, also confirming the “privileged” character of this 
pharmacophore, intrinsically suitable for an efficient interaction with a various biologic targets [17–
21]. A fine-tuning of curcumin covalent reactivity, by modulation of the target engagement rate, 
could represent a strategy through which avoiding the drawback of potential promiscuous reactions 
[22]. 
In the light of these concepts the main diarylheptadienone curcumin backbone was suitably 
modified for achieving specificity while retaining appropriate reactivity. By applying a click 
chemistry (CC) approach the curcumin scaffold was combined with a 1,2,3-triazole-based synthon 
bearing a para-fluorine and a para-methoxy benzyl moieties. In detail, this nitrogen-based heterocycle, 
obtained through the copper-catalyzed Huisgen 1,3-dipolar cycloaddition, could indeed represent a 
“privileged” fragment for drug discovery purposes, as it is expected to perform non-covalent 
interactions with a number of selected targets, offering an opportunity to obtain lead compounds 
endowed with an enriched efficacy profile. Certainly, this strategy has been largely exploited for the 
design of lead compounds for therapeutic applications among which the anticancer agents [23,24]. It 
has been acknowledged that design strategies based on “privileged sub-substructures” combination 
are a powerful tool to generate promising lead compounds [25]. The fluorine functionalization 
strategy demonstrated its pivotal role in providing valuable bioactive lead compound in several 
therapeutic areas [26–28]. 
Based on these considerations, a properly substituted benzyl 1,2,3-triazole structural unit was 
introduced into different positions of the curcumin scaffold and a small library of analogues was 
designed and synthesized (routes A, B and C, Figure 1). This strategy encompassed three main 
structural rearrangements: as a first step, by retaining the whole curcumin structure, 
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In spite of the notably favorable antitumor profile, several drawbacks have been reported for
curcumin among which poor chemical stability and aqueous solubility that negatively a↵ect its
bioavailability and cut the therapeutic window [12].
Curcumin, together with a large number of bioactive NPs, such as epigallocatechin gallate, quinone
and rifampicin, has recently been referred to as frequently hitter or pan-assay interfering compound
(PAIN) [13,14]. However, a large body of evidence supported that compound reactivity may be strictly
related to the structural environment. Thus, derivatives properly designed based on PAIN-based
synthons would perform as discriminating bioactive agents rather than reactive chemicals [15,16].
Extensive medicinal chemistry e↵orts have furnished support to this issue with the identification of a
large variety of successful curcumin-related molecules, obtained upon appropriate modifications of
its basic framework, also confirming the “privileged” character of this pharmacophore, intrinsically
suitable for an e cient interaction with a various biologic targets [17–21]. A fine-tuning of curcumin
covalent reactivity, by modulation of the target engagement rate, could represent a strategy through
which avoiding the drawback of potential promiscuous reactions [22].
In the light of these concepts the main diarylheptadienone curcumin backbone was suitably
modified for achieving specificity while retaining appropriate reactivity. By applying a click chemistry
(CC) approach the curcumin sca↵old was combined with a 1,2,3-triazole-based synthon bearing a
para-fluorine and a para-methoxy benzyl moieties. In detail, this nitrogen-based heterocycle, obtained
through the copper-catalyzed Huisgen 1,3-dipolar cycloaddition, could indeed represent a “privileged”
fragment for drug discovery purposes, as it is expected to perform non-covalent interactions with
a number of selected targets, o↵ering an opportunity to obtain lead compounds endowed with an
enriched e cacy profile. Certainly, this strategy has been largely exploited for the design of lead
compounds for therapeutic applications among which the anticancer agents [23,24]. It has been
acknowledged that design strategies based on “privileged sub-substructures” combination are a
powerful tool to generate promising lead compounds [25]. The fluorine functionalization strategy
demonstrated its pivotal role in providing valuable bioactive lead compound in several therapeutic
areas [26–28].
Based on these considerations, a properly substituted benzyl 1,2,3-triazole structural unit was
introduced into different positions of the curcumin scaffold and a small library of analogues was
designed and synthesized (routes A, B and C, Figure 1). This strategy encompassed three main structural
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rearrangements: as a first step, by retaining the whole curcumin structure, functionalization of the central
position of the heptatrienone tether was performed (route A, analogs 1 and 2); then, by maintaining the
unmodified central linker, modifications progressively involved the aryl side portions of the parent
synthon, i.e., in route B one vanillin-function was kept (analogs 3 and 4), whereas in route C both
the lateral moieties were decorated with the selected triazoles (compounds 5 and 6). These diversely
arranged curcumin analogs 1–6 allowed exploring the chemical space around the main skeleton, in the
light of drawing the essential features for achieving an improvement of the pharmacological profile,
in terms of biologic and physicochemical properties.
The newly synthesized analogs 1–6 were first evaluated for their cytotoxic potential, in comparison
to curcumin. The best performing candidate identified in this assay was then in-depth investigated to
unravel the molecular basis of its anticancer e↵ect in terms of proapoptotic and antiproliferative activities.
Particular attention was paid to disqualify a contingent PAIN behavior due to intrinsic autofluorescence.
2. Results
2.1. Synthesis
The curcumin-based analogs 1–6 were synthetized by exploiting the classical Pabon reaction [29],
while, to attain synthons conjugation, the copper-catalyzed azide–alkyne cycloaddition (CuAAC),
between the suitable azide (9 and 10) and alkyne (8 and 12) derivatives was performed (Schemes 1–3).
As depicted in Scheme 1, pentane-2,4-dione underwent an alkylation reaction with propargyl
bromide, in the presence of K2CO3 as base, to give 7 as mixture of  -keto-enol (KE) and diketo
(KK) tautomers; then, a Pabon reaction between 7 and 3-hydroxy-4-methoxy-benzaldehyde (vanillin),
in 1:1.8 stoichiometric ratio, allowed to obtain the curcumin-based intermediate 8 as a mixture of
KE and KK tautomers. Finally, 8 reacted with the azides 9 and 10 through the Huisgen reaction
a↵ording 1 and 2, respectively as tautomeric couples. Azide intermediates (9 and 10) were prepared by
a nucleophilic substitution reaction of the appropriate benzyl halides with NaN3. For the synthesis of
asymmetrical analogs 3 and 4 (Scheme 2) two sequential Pabon reactions were conducted [20], so that
pentane-2,4-dione was first reacted with 4-hydroxy-3-methoxybenzaldehyde in a 1:0.9 stoichiometric
ratio, to give the semisynthetic intermediate 11 [20] which was then reacted with the functionalized
aldehydes 13 and 14, to attain the desired asymmetrical compounds 3 and 4 in KE tautomeric
form. The aldehyde intermediates (13 and 14) were prepared via the CuAAC reaction between
the appropriate azides (9 and 10) and 4-(prop-2-yn-1-yloxy)benzaldehyde (12) obtained by reacting
4-hydroxybenzaldehyde and propargyl bromide under Williamson ether synthesis conditions. Finally,
Scheme 3 reports the synthetic route for the symmetrical analogs 5 and 6, starting from pentane-2,4-dione
and the selected aldehyde derivatives (13 and 14), respectively.
The functionalization of the central curcumin framework promoted the partial conversion of the
KE tautomer into the corresponding KK counterpart for derivatives 1, 2 and 8, (Scheme 1). In detail,
the propynyl-based compound 8, obtained as a mixture of KE/KK tautomers with a fairly di↵erent
chromatographic behavior, was carefully isolated by flash column chromatography, thus obtaining
8-KE in high purity grade. On the other hand, by inserting the benzyl 1,2,3-triazole moiety (1 and
2), it was not possible to obtain and isolate each single tautomer as chromatographically di↵erent
compound. Thus, additional 2D-NMR experiments (1H–1H COSY, 1H–13C HSQC, NOESY) were
performed on the tautomeric couple of derivative 1 to further confirm compound’s structure (Figures
S1–S5, Supplementary Materials). Finally, the introduction of the substituted 1,2,3-triazole ring system
on curcumin side aryl ring(s) (3–6) did not a↵ect the tautomeric conversion, thus maintaining the KE
tautomeric form.
Molecules 2020, 25, 3066 5 of 21
Molecules 2020, 25, x 5 of 21 
 
 
Scheme 1. Synthetic strategy for obtaining clicked curcumin-based compounds 1 and 2. Reagents and 
conditions: (i) propargyl bromide, K2CO3, acetone, 80 °C; (ii) B2O3, DMF; (iii) B(n- BuO)3; (iv) vanillin, 
n-BuNH2, 80 °C; (v) HCl, 80 °C; (vi) NaN3, DMF, 60 °C; (vii) TEA, CuSO4, (+)-sodium L-ascorbate, 
DMF, r.t. 
 
Scheme 2. Synthetic strategy for obtaining asymmetric clicked curcumin-based analogs 3 and 4. 
Reagents and conditions: (i) B2O3, DMF; (ii) B(n-BuO)3; (iii) n-BuNH2, 80 °C; (iv) HCl, 80 °C; (v) 
propargyl bromide, K2CO3, acetone, reflux; (vi) selected azide (9, 10), TEA, CuSO4, (+)-sodium L-
ascorbate, DMF, r.t. 
Scheme 1. Synthetic strategy for obtaining clicked c sed compounds 1 and 2. Reagents and
conditions: (i) propargyl bromide, K2CO3, aceto ,   ; (ii) 2 , ; (iii) B(n- BuO)3; (iv) vanillin,
n-BuNH2, 80  C; (v) HCl, 80  C; (vi) Na 3, D F, 60   ; (vii) TEA, CuSO4, (+)-sodium L-ascorbate,
DMF, r.t.
Molecules 2020, 25, x 5 of 21 
 
 
Scheme 1. Synthetic strategy for obtaining clicked curcumin-based compounds 1 and 2. Reagents and 
conditions: (i) propargyl bromide, K2CO3, acetone, 80 °C; (ii) B2O3, DMF; (iii) B(n- BuO)3; (iv) vanillin, 
n-BuNH2, 80 °C; (v) HCl, 80 °C; (vi) NaN3, DMF, 60 °C; (vii) TEA, CuSO4, (+)-sodium L-ascorbate, 
DMF, r.t. 
 
Scheme 2. Synthetic strategy for obtaining asymmetric clicked curcumin-based analogs 3 and 4. 
Reagents and conditions: (i) B2O3, DMF; (ii) B(n-BuO)3; (iii) n-BuNH2, 80 °C; (iv) HCl, 80 °C; (v) 
propargyl bromide, K2CO3, acetone, reflux; (vi) selected azide (9, 10), TEA, CuSO4, (+)-sodium L-
ascorbate, DMF, r.t. 
Scheme 2. Synthetic strategy for obtaining asymmetric clicked curcumin-based analogs 3 and 4. Reagents
and conditions: (i) B2O3, DMF; (ii) B(n-BuO)3; (iii) n-BuNH2, 80  C; (iv) HCl, 80  C; (v) propargyl bromide,
K2CO3, acetone, reflux; (vi) selected azide (9, 10), TEA, CuSO4, (+)-sodium L-ascorbate, DMF, r.t.
Molecules 2020, 25, 3066 6 of 21Molecules 2020, 25, x 6 of 21 
 
 
Scheme 3. Synthetic strategy for obtaining symmetric clicked curcumin-based analogs 5 and 6. 
Reagents and conditions: (i) B2O3, DMF; (ii) B(n- BuO)3; (iii) n-BuNH2, 80 °C; (iv) HCl, 80 °C. 
2.2. Biologic Evaluation 
2.2.1. Cytotoxicity 
The newly synthesized curcumin-based derivatives 1–6 were evaluated for their cytotoxic effect 
on T acute lymphoblastic leukemia cell line (CCRF–CEM) after 24- and 48-h treatment and data 
reported are in Table 1 and Figure 2. All derivatives, with the exception of 3, decreased cell viability 
in a time-dependent manner (Figure 2). After 24 h treatment, compounds 1–3 showed IC50 values in 
the two-digit-µM level, proving to be the most potent of the series, more active than curcumin, for 
which an IC50 higher than 150 µM was observed. Interestingly, after 48-h treatment, a high potency 
was observed for curcumin and derivatives 1 and 2 (IC50 = 10.51, 3.13 and 3.95 µM, respectively). 
Here, the conjugation of the 1,2,3-triazole-based synthon with the unmodified curcumin framework 
proved to be particularly favorable for antiproliferative effect that resulted more than three times 
higher than that of curcumin itself. On the other hand, a mild to low antiproliferative effect was 
observed for the linearly arranged compounds 3–6 (IC50 values ranging from 38.00 to 93.40 µM). In 
detail, when compared to 1 and 2, molecules 3 and 4, characterized by a mixed vanillin–triazole 
fragment combination (i.e., in which one vanillin-based ring was maintained while the other side aryl 
function was decorated with the selected 1,2,3-triazole-based synthons), showed a substantial 
decreased activity (IC50 = 38.00 and 69.07 µM, respectively) giving the fluorine functionalization the 
best result. The decoration of both aryl moieties with the 1,2,3-triazoles–synthons turned out into a 
further reduction of the antiproliferative effect (IC50 = 88.94 and 93.40 µM), suggesting that the 
presence of the vanillin ring is of pivotal importance for inhibition of CCRF–CEM cell proliferation. 
This results trend was helpful and supportive for the pursued design strategy. 
Based on these data, derivative 1, due to its good low-µM cytotoxic effect was chosen as 
prototype compound for deeper evaluations aimed at better understanding its mechanism of action. 
This analog may be interesting from a pharmacokinetic perspective, due to the presence of a fluorine 
atom that was well-acknowledged to favorably affect pKa, lipophilicity and metabolic stability [30]; 
moreover, this substituent, could also improve both binding interactions and selective reactivity of 
the molecule [31], thus providing an enhancement of the therapeutic outcome. 
To investigate the anticancer potential of compound 1 on CCRF–CEM cells, a screening pipeline 
was established in which, the effect on cell-cycle progression was first evaluated. Then, a possible 
pro-apoptotic effect was determined by a preliminary study on cell membrane structure and 
integrity. Moreover, mitochondrial potential variation and caspase-8 activity were analyzed to 
evaluate the impact of 1 on intrinsic and extrinsic apoptosis pathways, respectively. Of note, 
concentrations that do not exceed its IC50 value were employed for these studies, to avoid that non-
programmed cell death could take over on a regulated mechanism of action. 
  
Scheme 3. Synthetic strategy for obtaining symmetric clicked curcumin-based analogs 5 and 6. Reagents
and conditions: (i) B2O3, DMF; (ii) B(n- BuO)3; (iii) n-BuNH2, 80  C; (iv) HCl, 80  C.
2.2. Biologic Evaluation
2.2.1. Cytotoxicity
The newly synthesized curcumin-based derivatives 1–6 were evaluated for their cytotoxic e↵ect
on T acute lymphoblastic leukemia cell line (CCRF–CEM) after 24- and 48-h treatment and data
reported are in Table 1 and Figure 2. All derivatives, with the exception of 3, decreased cell viability
in a time-dependent manner (Figure 2). After 24 h treatment, compounds 1–3 showed IC50 values
in the two-digit-µM level, proving to be the most potent of the series, more active than curcumin,
for which an IC50 higher than 150 µM was observed. Interestingly, after 48-h treatment, a high potency
was observed for curcumin and derivatives 1 and 2 (IC50 = 10.51, 3.13 and 3.95 µM, respectively).
Here, the conjugation of the 1,2,3-triazole-based synthon with the unmodified curcumin framework
proved to be particularly favorable for antiproliferative e↵ect that resulted more than three times
higher than that of curcumin itself. On the other hand, a mild to low antiproliferative e↵ect was
observed for the linearly arranged compounds 3–6 (IC50 values ranging from 38.00 to 93.40 µM).
In detail, when compared to 1 and 2, molecules 3 and 4, characterized by a mixed vanillin–triazole
fragment combination (i.e., in which one vanillin-based ring was maintained while the other side
aryl function was decorated with the selected 1,2,3-triazole-based synthons), showed a substantial
decreased activity (IC50 = 38.00 and 69.07 µM, respectively) giving the fluorine functionalization the
best result. The decoration of both aryl moieties with the 1,2,3-triazoles–synthons turned out into
a further reduction of the antiproliferative e↵ect (IC50 = 88.94 and 93.40 µM), s ggesting that the
presence of the vanillin ring is of pivotal importance for inhibition of CCRF–CEM cell proliferat on.
T is results re d was helpful and supportive for the pursued design strategy.
Based on these data, derivative 1, due to its good low-µM cy otoxic e↵ect was chosen as prototype
compound for eeper evaluatio s aimed at b tter understanding its mechanism of action. This analog
may be interesting from a pharmacokinetic perspective, due to the presence of a fluorine atom that was
well-acknowledged to favorably a↵ect pKa, lipophilicity and metabolic stability [30]; moreover, this
substituent, could also improve both binding interactions and selective reactivity of the molecule [31],
thus providing an enhancement of the therapeutic outcome.
To investigate the anticancer potential of compound 1 on CCRF–CEM cells, a screening pipeline
was established in which, the e↵ect on cell-cycle progression was first evaluated. Then, a possible
pro-apoptotic e↵ect was determined by a preliminary study on cell membrane structure and integrity.
Moreover, mitochondrial potential variation and caspase-8 activity were analyzed to evaluate the
impact of 1 on intrinsic and extrinsic apoptosis pathways, respectively. Of note, concentrations that do
not exceed its IC50 value were employed for these studies, to avoid that non-programmed cell death
could take over on a regulated mechanism of action.
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Table 1. Cytotoxic effect of compounds 1–6 against T acute lymphoblastic leukemia cell line (CCRF–CEM).
Compound R
CCRF–CEM Cell Line IC50 (µM) a
24 h 48 h
1
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2.2.2. Cell-Cycle Progression
Since during the cytotoxicity assays a decrease in the number of cells was noticed for compound
1, the ability of this derivative to a↵ect cell proliferation was investigated, and its e↵ect on cell-cycle
progression was analyzed. CCRF–CEM cells were treated with 1.5 and 3.0 µM concentrations of 1 for
24 h; at the end of the treatment, no cell-cycle block was recorded at any tested concentration. However,
as foretold from cytotoxicity experiments, cell death proved to be the primary mechanism of action of
the antitumor potential of analog 1. Indeed, a significant increase in the fraction of the subG0 phase,
which represents the fraction of cells with fragmented DNA, was recorded (Figure 3).
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2.2.3. Phosphatidylserine Exposure and Cell Death Analysis
A loss in plasma membrane asymmetry has been recognized as an early event in dead cells,
accompanied by urface exposure of phosphatidylserine (PS) residues, wher as the int grity of
the embrane remains unhamp red. Surface exposed PS can be detected by its a nity for
phospholipid binding protein annexin V (AV) [32]. On the contrary, both late apoptotic and necr ptotic
cells su↵er the loss of membrane i tegrity, resulting thus permeable to vital dyes namely he DNA
inte calator 7-amino-actinomycin (7-AAD) regarded as marker of membrane integrity [33]. According ,
o di↵erentiate e ls undergoing early cell death from lat cell death (i.e., apoptotic and necroptot c ones),
V/7-AAD binding assay, followed by flow cytometry analysis, was performed allowing to identify
cells in the early cell death stage (7AAD /AV+), ate cell death stage (7AAD+/AV+) and completely
dead cells (7AAD+/ AV ) [34]. CCRF–CEM cells were treated with 1.5 an 3 µM concentrations of
comp und 1 for 24 h and tained by using AV and 7-AAD. In general, an increase in the fraction of
AV-positive cells was observed. At the highest tested do e, the percentage of cells at the e rly stages
of cell dea h (AV+/7-AAD ) was 53.4. Howe r, 22.3% were the c lls in the late stages of c ll death
togeth r with necrotic cells (AV+/7-AAD+), compared to 8.0% and 3.3%, resp c ively, recorded for
untr ated cel s (Figure 4A).
The c totoxic and proapop oti potential of compound 1 was also tested and confirmed on
a di↵er nt tumor cell line, the acute T c ll leukemia Jurkat (Figure S6, Supplementary Materials).
Since PS exp sure is an event that haracterizes both caspase-dependent and -independent types
of c ll death [35], to exclude that beside apop osis di↵erent forms of regulated cell dea h concur to
compound 1 antitumor potential, we used specific cell death inhibitors: (zVAD-fmk, pan-caspase
blocker), necroptosis [necrostatin-1 s (N c1 ), a RIPK1 inhibitor] or fe roptosis [ferrostatin-1 (fer-1),
an inhibitor of reactive oxygen specie and lipid peroxidation and deferoxamine (DFO), an iron chelator
to characterize apop osis, necroptosis or ferroptosis, r spectively [36,37]. Only zVAD-fmk was able to
rescue cells after exposure to compound 1. Thus, this outcome indicat s that compound 1 triggers
mere apoptotic cell death.
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2.2.4. Mitochondrial Transmembrane Potential
In normal cells, the mitochondrial transmembrane potential (MTP, DYm) plays a key role in
preserving the function of the respiratory chain, aimed at ATP generation. During poptosis, MTP
disruption occurs, leading to disturbance of the mitochondrial outer m mbrane permeabilization and
collapse of the electrochemical gradient acr ss the membrane [38]. Thus, to evaluate th involvement
of the intrinsic pathway, the de ree of MTP reduction on CCRF–CEM was determined. The cells,
after treatme t with compound 1 at 3 µM, were stained by using the membrane permeable lipophilic
cation 1,10,3,3,30,30-hexa ethylindodicarbo-cyanine io ide DiIC1(5) and its mitochondria level was
determined by a flow cytometry analysis. In apopt tic cells, a reduced fluorescence intensity is
the indication of MTP disruption, due to the localization of the dye into the cytoplasm. Figure 5A
shows the percentage of viable cells su↵ering a loss of MTP after 1.5 and 3 µM treatment (24 h) with
compound 1. In particular, at 3 µM, 55.9% of 1-treated cells showed a loss in MTP, clearly demonstrating
the inv lvement of mitochondria pathway-mediated cell death in its anticancer e↵ect. In accordance,
around 95% of them were in the early cell death phase, as indicated by AV+/7-AAD  assay outcome
(Figure 5B).
2.2.5. Caspase-8
Our data on kinetics of PS exposure and MTP suggest that compound 1 induces apoptotic cell
death in leukemia cells. In order to identify the type of cell death, caspase-8 activity was measured [34].
Th init ator caspase-8 could be considered a connection point be ween rec ptor and mitochondrial
pathways and its activity llows to discriminate apoptotic cell death from necroptosis [39]. Death
receptors stimulation results in caspase-8 activation, which, in urn, by dire tly cleaving downstream
e↵ector c spases, can spread p ptosis sig al. On the other side, activatio of caspase-8 may r sult
in cleavage of Bid, which translocates to mitochondria to release cytochrom c, hereby initiating
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a mitochondrial amplification loop [40]. Thus, the intracellular e↵ect of compound 1 on caspase-8
activity, as representative for the extrinsic apoptosis signaling pathways, was examined and results
were expressed as percentage of apoptotic cells with active caspase-8 (Figure 5C). Compound 1 at
the highest tested concentration proved to promote a significant activation (26.7%) of caspase-8 in
apoptotic cells.
These data reveal that derivative 1 activates both apoptosis signaling pathways, potentially
inducing an optimal activation of the apoptotic machinery.
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**** p < 0.0001 versus untreated cells. CCCP: carbonyl cyanide 3-chlorophenylhydrazone. C-: control.
2.2.6. Physicochemical Properties Prediction
Taking cur umin burdens into account, and in order to preliminarily exclude the possibility that
the synthetized derivatives could act as promiscuous bioactive molecules [41], compounds 1–6 were
analyzed for their assay interference potential according to three di↵erent in silico tools: FAFDrugs4
(http://fafdrugs4.mti.univ-paris-diderot.fr/) [42], False Positive Remover (http://www.cbligand.org/
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PAINS/) [43] and Aggregator Advisor. (http://advisor.bkslab.org/) [44]. All derivatives were not
recognized as potential PAINS or aggregators (Tables S1–S3, Supplementary Materials).
2.2.7. FACS analysis to Study PAINS-Like Behavior
Autofluorescence is one cause of general assays interference and characterizes at least 3.1%
of PAINS [16]. As many biologic assays exploit fluorescent probes, autofluorescence is one of the
trickiest aspects that mislead about the activity of a compound. False-positive or -negatives are the
severe consequences. Aware of this, and since flow cytometry was used to perform all the biologic
experiments, compounds’ autofluorescence was taken into account and dealt with.
First, we had to get the lay of the land. In the FACS, unstained cell samples (i.e., with no additional
probe) treated with the same concentrations of compounds and time points used for the real biologic
assays were run. Two different lasers 488 nm (blue) or 642 nm (far-red), were employed to excite samples.
Empirically, it was remarked that all unstained compounds emit fluorescence only if excited with the
blue laser. After excitation with this laser, light was filtered and assigned into three emission channels:
green, yellow and red. Cells treated with compounds 1–6 showed high green fluorescence intensity and
low yellow and red ones. With this in mind and since each probe has specific characteristics such as
brightness and intensity, for each assay the setting had to be adjusted, in terms of voltage and the signal
was compensated in order to cancel the autofluorescence of the analyzed compound.
As expected, the green channel was the most laborious to manage and it was adjusted for caspase-8
activity detection since the caspase-8 substrate emits there. Specifically, with the Guava easyCyte
6HT-2L, it was not possible lower autofluorescence of compound 1 enough to allow performing the
experiment. To cope with this situation, the more performant BD FACS Canto cytometer was employed.
Figure S7 (Supplementary Materials) shows the gating strategy for that analysis and the successful
management of green autofluorescence of 1. Furthermore, a similar, very recent methodologic approach
was applied by Sala de Oyanguren and coworkers, who successfully managed the relevant green
autofluorescence of curcumin and the specific signal of a green-emitting dye, as YO-PRO-1 [45].
The interference between any other probe and the compounds’ autofluorescence was handled in the
same way. The only exception was that samples were recorded with the FACS Guava. For instance,
for the proliferation assay, the red-emitting dye 7-AAD was used. Compounds’ red-autofluorescence
was easily displaced and did not interfere with the 7-AAD ones. Over and above, to be sure that
artifacts were not recorded, in parallel, FACS results were compared with those obtained by the eosin
exclusion dye without observing any significant discordance (data not shown). Conducting cell-cycle
analysis was even easier. Indeed, after cell fixation and permeabilization, autofluorescence of derivative
1 was utterly gone (data not shown). Thus, no special adjust setting or compensation was necessary.
Last, for apoptosis analysis, 7-AAD and AV–phycoerythrin, which emits in the yellow channel, were
used. To combine the phycoerythrin signal to those of 7-AAD and compound 1 resulted in perfectly
manageable compensation analysis. All probes used for the remaining biologic assays were excited
by 642 nm laser, so we did not experience any trouble. In conclusion, taking into considerations all
these aspects we avoided to produce false results and provided solid data demonstrating that as far as
autofluorescence is concerned, these derivatives do not behave like PAINS.
2.2.8. Chemical Stability Study
Conscious of the chemical stability liability that may a↵ect the curcumin sca↵old, the chemical
stability of 1 as mixture of  -keto-enol form and its diketo tautomeric counterpart were studied by
RP-HPLC. In detail, a previously reported methodology was applied, and in the working conditions,
no degradation products formation was observed (Figure S8, Supplementary Materials).
3. Discussion
Herein we reported the design, synthesis and biologic evaluation of a small library of curcumin-
triazole conjugates. The conjugation of the “privileged” curcumin framework and triazole-based
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para-fluorine or para-methoxy benzyl moieties, allowed obtaining analogs 1–6 that were analyzed for
their cell growth inhibitory e↵ects on T acute lymphoblastic leukemia cells. The data showed that
compounds 1 and 2, both characterized by the unmodified curcumin–sca↵old, significantly inhibited
cancer cell line growth with IC50 values in the low-µM range. The potency of 1, proved to be more
than three times higher than that of its precursor curcumin, and this compound was selected for
deeper evaluation in order to assess the molecular basis of its anticancer profile. The induction of
apoptotic process turned out to be the molecular mode by which compound 1 induced cell death. Its
peculiar ability to a↵ect both the intrinsic and the extrinsic pathways represents a significant added
value, useful to achieve a strengthening in anticancer outcome in terms of cytotoxic response and
decreased predisposition of chemoresistance insurgence. However, this evidence would be worthless
if the compound under assessment is a PAIN, in other words if the favorable results are just artefacts.
Chelation, covalent modifications, redox e↵ect, and autofluorescence are only some of the conditions
that push drug candidates into the PAINS qualification [16]. In this study, we focused our attention on
the autofluorescence of the derivatives and we e ciently prevented its interference with the biologic
assays. We analyzed just one part of the “PAIN puzzle” and our results suggest, but do not prove, that
compound 1 is not a PAIN. Certainly, our data represent an interesting premise to keep on exploring
antitumor potential of 1 while keeping our eyes wide open.
4. Materials and Methods
4.1. Chemistry
Chemical reagents and solvents, unless otherwise specified, were employed as commercial
products with a high-grade purity. Reaction courses were monitored by thin-layer chromatography
(TLC) performed on precoated TLC plates (Silica Gel 60 F254, layer 0.20 mm, Merck, Darmstadt,
Germany) and then visualized under a UV lamp (  = 254 and 365 nm). Chromatographic separations
were performed on silica gel columns by using the flash method (flash column chromatography
(FCC), Kiesegel 40, particle size 0.040–0.063 mm, Merck, Darmstadt, Germany). Melting points were
determined in open glass capillaries, using a Büchi apparatus (Büchi Italia s.r.l., Cornaredo, MI, Italy)
and are uncorrected. 1H NMR and 13C NMR spectra were recorded on Varian INOVA spectrometer
(Scientific instruments, Palo Alto, CA, USA) operating at 400 MHz and 101 MHz, respectively; data are
reported as follows: chemical shift (ppm   value), multiplicity (indicated as: br., broad signal; s, singlet;
d, doublet; t, triplet; q, quartet; p, quintet; m, multiplet and combinations thereof), coupling constants
(J) in Hertz (Hz) and integrated intensity. Mass spectra were recorded on a Waters ZQ 4000 apparatus
(Waters Alliance, San Diego, CA, USA) operating in electrospray mode (ES). All tested compounds
were found to have >95% purity, as determined by HPLC analysis, performed on a chromatograph
PU-1587 UV model equipped with a 20 µL loop valve (Jasco Europe, Italy) by using a Phenomenex
Luna 5 µm C18 column (150 ⇥ 4.60 mm) as stationary phase and a mixture of H2O/MeCN (50:50, v/v)
for 1 and 2, H2O/MeCN (35:65, v/v) for 3–6 as mobile phase; detection at   = 254 nm, flow rate of
1.0 mL/min. Compounds name is in accord with the naming algorithm developed by CambridgeSoft
Corporation used in Chem-BioDraw Ultra 19.1 (Perkin Elmer, Waltham, MA, USA.
4.1.1. Huisgen 1,3-Dipolar Cycloaddition. General Procedure for the Synthesis of Curcumin-Triazole
Conjugates 1, 2 and Intermediates 13, 14
To a solution of the corresponding alkyne 8 or 12 (1.00 mmol) and azide 9 or 10 (1.3 molar equiv)
in DMF (7.50 mL), TEA (0.1 molar equiv) was added dropwise, followed by a water solution of CuSO4
(0.1 molar equiv) and (+)-sodium L-ascorbate (0.5 molar equiv). The resulting mixture was stirred for
2–18 h at rt and the reaction progress was monitored by TLC. Upon reaction completion, the solution
was poured into H2O and the formed solid was filtered o↵ and dried under vacuum.




According to the general procedure, 8-KE/KK (0.24 g, 0.60 mmol) and 9 (0.12 g, 0.78 mmol) were
allowed to react for 18 h. The crude product was purified by FCC on silica gel (EP/EtOAc 1:1) and
further crystallized from DCM/EP to obtain 1-KE/KK as a red solid (0.18 g, 1.0:1.1 mixture ratio of
KE/KK tautomer), 41% yield, mp 95–97  C. 1H NMR (CDCl3)   3.38 (d, J = 7.2 Hz, 2H, CH2, KK), 3.91
(s, 12H, OCH3, KE+KK), 4.06 (s, 2H, CH2, KE), 4.76 (t, J = 7.2 Hz, 1H, CH, KK), 5.40 (s, 4H, CH2 N,
KE+KK), 5.92 (br, 2H, OH, KE), 5.98 (br, 2H, OH, KK), 6.67 (d, J = 16.0 Hz, 2H, CH=CH, KK), 6.81–6.88
(m, 4H, Ar and CH=CH, KE), 6.91 (d, J = 8.0 Hz, 4H, H-5, KK+KE), 6.93–6.99 (m, 4H, Ar and H-2,
KE), 7.01 (s, 2H, H-2, KK), 7.03–7.11 (m, 6H, Ar and H-6, KK+KE), 7.14–7.18 (m, 2H, Ar), 7.26 (s, 2H,
CH-triazole, KE+KK), 7.58 (d, J = 15.6 Hz, 2H, CH=CH, KK), 7.67 (d, J = 15.2 Hz, 2H, CH=CH, KE).
13C NMR (CDCl3)   23.4 (CH2, KE), 24.9 (CH2, KK), 53.4 (CH2 N), 53.6 (CH2 N), 56.2 (4C, OCH3), 63.1
(CH), 77.4, 107.8 (2C, CH), 109.8 (4C, CH), 115.0 (4C, CH), 116.2 (d, J = 21.8 Hz, 4C, CH), 117.9 (2C,
CH=CH, KE), 122.0 (2C), 122.1 (2C, CH=CH, KK), 122.2, 123.4 (2C, CH), 124.3 (2C, CH), 126.8 (2C),
127.9 (2C), 129.7 (d, J = 8.4 Hz, 2C, CH), 129.9 (d, J = 8.4 Hz, 2C, CH), 130.6 (d, J = 3.2 Hz), 130.7 (d,
J = 3.2 Hz), 142.5 (2C, CH=CH, KE), 145.3 (2C, CH=CH, KK), 145.4 (2C), 148.2 (d, J = 255.6 Hz, 2C),
147.0 (2C), 148.3 (2C), 148.9 (2C), 183.3 (2C), 194.6 (2C). ESI-MS (m/z) 580 (M + Na).
The same reaction was performed starting from 8-KE and 1-KE/KK was obtained as 1.3:1.0




Following the general procedure, 8-KE/KK (0.36 g, 0.89 mmol) and 10 (0.19 g, 1.15 mmol) were
allowed to react for 18 h. Purification by FCC (EP/EtOAc 7:3) and further crystallization from DCM/EP
gave 2-KK/KE as a red solid (0.22 g, 1.0:1.3 mixture ratio of KE/KK tautomer), 43% yield, mp 98–100  C.
1H NMR (CDCl3)   3.35 (d, J = 7.2 Hz, 2H, CH2, KK), 3.68 (s, 3H, OCH3, KE), 3.72 (s, 3H, OCH3, KK),
3.90 (s, 12H, OCH3, KE+KK), 4.03 (s, 2H, CH2, KE), 4.74 (t, J = 7.2 Hz, 1H, CH, KK), 5.35 (s, 4H, CH2 N,
KE+KK), 5.88 (br, 2H, OH, KK), 5.92 (br, 2H, OH, KE), 6.65 (d, J = 6.8 Hz, 4H, H-5, KE+KK), 6.68 (s,
4H, H-2, KE+KK), 6.78 (d, J = 8.8 Hz, 4H, H-6, KE+KK), 6.83 (d, J = 15.2 Hz, CH=CH, 2H, KK), 6.89
(d, J = 8.0 Hz, 4H, Ar, KE+KK), 6.95 (s, 1H, CH-triazole, KE), 7.00 (s, 1H, CH-triazole, KK), 7.04 (d,
J = 8.4 Hz, 4H, Ar, KE+KK), 7.11 (d, J = 15.2 Hz, 2H, CH=CH, KE), 7.56 (d, J = 15.6 Hz, 2H, CH=CH,
KK), 7.66 (d, J = 15.6 Hz, 2H, CH=CH, KE). 13C NMR (CDCl3)   23.4, 24.8, 29.8, 53.7, 53.9, 55.3, 55.4,
56.1 (2C), 56.2 (2C), 62.9, 107.8 (2C), 109.8 (2C), 109.9 (2C), 114.4 (2C), 114.5 (2C), 114.9 (2C), 115.0 (2C),
117.9, 121.9, 122.1 (2C), 123.5 (2C), 124.3 (2C), 127.6 (2C), 127.9 (2C), 129.3 (2C), 129.6 (2C), 129.7, 142.5,
145.1 (2C), 145.3 (2C), 147.0 (2C), 148.3 (2C), 149.0 (2C), 149.2 (2C), 159.9 (2C), 183.2 (2C), 194.6 (2C).
ESI-MS (m/z): 592 (M + Na).
The same reaction was performed starting from 8-KE and 2-KE/KK was obtained as 1.0:1.2
mixture ratio of KE/KK tautomers.
4-((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)benzaldehyde (13).
In line with the general procedure, 12 (0.19 g, 1.20 mmol) and 9 (0.24 g, 1.55 mmol) were allowed
to react for 2 h. The formed solid was collected by vacuum filtration to a↵ord 13 (0.16 g) as pure solid,
43% yield, mp 88–90  C. 1H NMR (CDCl3)   5.25 (s, 2H, OCH2), 5.51 (s, 2H, CH2 N), 7.04–7.09 (m, 4H,
Ar), 7.28 (d, J = 8.4 Hz, 2H, Ar), 7.51 (s, 1H, CH-triazole), 7.82 (d, J = 8.4 Hz, 2H, Ar), 9.88 (s, 1H, CHO).
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4-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)benzaldehyde (14).
In line with the general procedure, 12 (0.21 g, 1.28 mmol) and 10 (0.27 g, 1.67 mmol) were allowed
to react for 3 h. The formed solid was collected by vacuum filtration to a↵ord 14 (0.25 g) as pure solid,
60% yield, mp 83–85  C. 1H NMR (CDCl3)   3.81 (s, 3H, OCH3), 5.25 (s, 2H, OCH2), 5.48 (s, 2H, CH2
N), 6.90 (d, J = 8.4 Hz, 2H, Ar), 7.08 (d, J = 8.4 Hz, 2H, Ar), 7.24 (d, J = 8.4 Hz, 2H, Ar), 7.51 (s, 1H,
CH-triazole), 7.83 (d, J = 8.4 Hz, 2H, Ar), 9.89 (s, 1H, CHO).
4.1.2. Pabon Reaction. General Procedure for the Synthesis of Curcumin-Triazole Conjugates 3–6 and
Intermediates 8 and 11
A suspension of 2,4-dicarbonyl compound (pentane-2,4-dione, intermediates 7 or 11 [20], 1.00 mmol)
and B2O3 (1.0 molar equiv) in DMF (1.50 mL), was heated for 30 min at 80  C, then B(n-BuO)3 (2.0 molar
equiv for 3, 4 and 11, or 4.0 molar equiv for 5, 6 and 8 derivatives) was added and the resulting mixture
was heated at the same temperature for additional 30 min. Afterward, a solution of the suitable aldehyde/s,
(0.9 molar equiv for 3, 4 and 11 or 1.8 molar equiv for 5, 6 and 8) in DMF (1.00 mL) was added, followed
by a n-BuNH2 solution (0.2 molar equiv for 3, 4 and 11, or 0.4 molar equiv for 5, 6 and 8, in 1.00 mL of
DMF). After stirring at 80  C for 6–8 h, the resulting mixture was cooled to rt, acidified with HCl (0.5 N,
8.0 mL) and stirred at 80  C for further 30 min. On cooling, a solid product precipitates, which was
separated by vacuum filtration. The obtained crude was suspended in H2O, filtered and purified by FCC
and/or crystallization from suitable solvent or mixture of solvents, to afford the title pure compound.
(1E,4Z,6E)-1-(4-((1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-5-hydroxy-7-(4-hydroxy-
3-methoxyphenyl)hepta-1,4,6-trien-3-one (3).
Following the general procedure, reaction of intermediate 11 (0.07 g, 0.29 mmol) and the aldehyde
13 (0.08 g, 0.26 mmol) gave the crude which was purified by FCC (PE/EtOAc 6:4) and further
crystallization from EtOH to obtain 3 as an orange powder (0.05 g), 40% yield, mp 113–115  C. 1H
NMR (CDCl3)   3.95 (s, 3H, OCH3), 5.23 (s, 2H, CH2 N), 5.52 (s, 2H, OCH2), 5.80 (s, 1H, CH), 6.49 (d,
J = 15.6 Hz, 1H, CH=CH), 6.50 (d, J = 15.6 Hz, 1H, CH=CH), 6.94 (d, J = 8.4 Hz, 1H, H-5), 6.99 (d,
J = 7.6 Hz, 2H, Ar), 7.06 (s, 1H, H-2), 7.07 (d, J = 7.6 Hz, 1H, H-6), 7.08–7.14 (m, 2H, Ar), 7.24–7.27 (m,
2H, Ar), 7.50 (d, J = 8.0 Hz, 2H, Ar), 7.55 (s, 1H, CH-triazole), 7.60 (d, J = 15.6 Hz, 1H, CH=CH), 7.61 (d,
J = 16.0 Hz, 1H, CH=CH). 13C NMR (CDCl3)   53.7, 56.1, 62.2, 101.5, 109.7, 114.9, 115.3 (2C), 116.4 (d,
J = 21.4 Hz, 2C), 121.9, 122.3, 122.7, 123.1, 127.8, 128.5, 129.9 (2C), 130.0, 130.2 (d, J = 8.1 Hz, 2C), 140.0,
140.8, 144.4, 146.9, 148.0, 159.9, 160.7 (d, J = 249.4 Hz), 183.2, 183.6. ESI-MS (m/z): 550 (M + Na).
(1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-
4-yl)methoxy)phenyl)hepta-1,4,6-trien-3-one (4).
According to the general procedure, reaction of intermediate 11 (0.20 g, 0.86 mmol) and the
aldehyde 14 (0.25 g, 0.77 mmol) gave the crude which was purified by FCC (PE/EtOAc 6:4) and further
crystallization from EtOH to give 4 as an orange-brown powder (0.19 g), 45% yield, mp 149–151  C. 1H
NMR (CDCl3)   3.82 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.22 (s, 2H, OCH2), 5.48 (s, 2H, NCH2), 5.80 (s,
1H, CH), 5.88 (br, 1H, OH), 6.49 (d, J = 15.6 Hz, 1H, CH=CH), 6.50 (d, J = 16.0 Hz, 1H, CH=CH), 6.91 (d,
J = 8.4 Hz, 2H, Ar), 6.94 (d, J = 8.0 Hz, 1H, H-5), 6.99 (d, J = 8.8 Hz, 2H, Ar), 7.06 (d, J = 1.6 Hz, 1H, H-2),
7.13 (dd, J = 1.6 and 8.4 Hz, 1H, H-6), 7.25 (d, J = 8.8 Hz, 2H, Ar), 7.50 (d, J = 8.8 Hz, 2H, Ar), 7.51 (s, 1H,
CH-triazole), 7.60 (d, J = 16.0 Hz, 1H, CH=CH), 7.61 (d, J = 16.0 Hz, 1H, CH=CH). 13C NMR (CDCl3)  
53.9, 55.5, 56.1, 62.2, 101.5, 109.7, 114.6 (2C), 115.0, 115.3 (2C), 121.7, 122.2, 122.6, 123.1, 126.4, 127.8,
128.4, 129.9 (4C), 140.0, 140.7, 144.1, 147.0, 148.0, 159.9, 160.1, 183.2, 183.6. ESI-MS (m/z): 538 (M—H).
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(1E,4Z,6E)-1,7-bis(4-((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-5-hydroxyhepta-1,4,6-
trien-3-one (5).
In line with the general procedure, reaction of pentane-2,4-dione (0.03 mL, 0.29 mmol) and the
aldehyde 13 (0.16 g, 0.52 mmol) gave the crude product which was purified by FCC (PE/EtOAc 1:1) and
further crystallization from DCM/PE to a↵ord 5 as a yellow powder (0.07 g), 35% yield, mp 134–136  C.
1H NMR (CDCl3)   5.22 (s, 4H, OCH2), 5.52 (s, 4H, CH2 N), 5.79 (s, 1H, CH), 6.51 (d, J = 15.6 Hz, 2H,
CH=CH), 7.00 (d, J = 8.8 Hz, 4H, Ar), 7.06–7.10 (m, 4H, Ar), 7.27–7.30 (m, 4H, Ar), 7.51 (d, J = 8.4 Hz,
4H, Ar), 7.54 (s, 2H, CH-triazole), 7.62 (d, J = 15.6 Hz, 2H, CH=CH). 13C NMR (CDCl3):   53.7 (2C),
62.2 (2C), 101.5, 115.3 (4C), 116.35 (d, J = 21.4 Hz, 4C), 121.9, 122.3, 122.7 (2C), 128.5 (2C), 129.9 (4C),
130.0 (2C), 130.2 (d, J = 8.1 Hz, 4C), 140.0, 140.8, 144.4 (2C), 160.0 (2C), 160.7 (d, J = 249.4 Hz, 2C), 183.2,
183.6. ESI-MS (m/z): 687 (M + H).
(1E,4Z,6E)-5-hydroxy-1,7-bis(4-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)hepta-
1,4,6-trien-3-one (6).
Following the general procedure, reaction of pentane-2,4-dione (0.09 mL, 0.86 mmol) and the
aldehyde 14 (0.50 g, 1.55 mmol) gave the crude product which was purified by FCC (PE/EtOAc 1:1)
a↵ording 6 as an orange-brown powder (0.18 g), 30% yield, mp 173–175  C. 1H NMR (CDCl3)   3.82 (s,
6H, OCH3), 5.22 (s, 4H, OCH2), 5.48 (s, 4H, CH2 N), 5.79 (s, 1H, CH), 6.48 (d, J = 15.6 Hz, 2H, CH=CH),
6.88 (d, J = 8.0 Hz, 4H, Ar), 6.97 (d, J = 8.0 Hz, 4H, Ar), 7.25 (d, J = 8.0 Hz, 4H, Ar), 7.48 (d, J = 8.0 Hz,
4H, Ar), 7.48 (s, 2H, CH-triazole), 7.59 (d, J = 15.6 Hz, 2H, CH=CH). 13C NMR (CDCl3)   54.0 (2C), 55.5
(2C), 62.3 (2C), 101.6, 114.7 (4C), 115.4 (4C), 122.3 (2C), 122.6 (2C), 126.5 (2C), 128.5 (2C), 129.9 (8C),
134.7, 140.1, 144.2 (2C), 160.2 (2C), 167.3 (2C), 183.4 (2C). ESI-MS (m/z): 733 (M + Na).
(1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-4-(prop-2-yn-1-yl)hepta-1,4,6-trien-3-one
(8-KE); (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-4-(prop-2-yn-1-yl)hepta-1,6-diene-3,5-dione (8-KK).
Following the general procedure, reaction of 7 (0.36 g, 2.61 mmol) and 3-methoxy-4-
hydroxybenzaldehyde (0.71 g, 4.70 mmol) gave a crude product which was purified by FCC (PE/EtOAc
7:3) and further crystallization from EtOH. In this case, the desired compound was isolated as 8-KE
pure and as 1.0:1.7 mixture of 8-KK/KE tautomers (0.61 g), 58% yield, mp 144–147  C. 8-KE: 1H NMR
(CDCl3)   2.15 (t, J = 2.4 Hz, 1H, C⌘CH), 3.44 (d, J = 2.4 Hz, 2H, CH2C⌘), 3.96 (s, 6H, OCH3), 5.89
(br, 2H, OH), 6.95 (d, J = 8.0 Hz, 2H,H-5), 6.99 (d, J = 15.4 Hz, 2H, CH=CH), 7.07 (d, J = 2.0 Hz, 2H,
H-2), 7.20 (dd, J = 8.0 and 2.0 Hz, 2H, H-6), 7.73 (d, J = 15.4 Hz, 2H, CH=CH). 8-KK/KE: 1H NMR
(CDCl3)   2.15 (t, J = 2.4 Hz, 2H, C⌘CH, KK+KE), 2.91 (dd, J = 7.4 and 2.4 Hz, 2H, CH2C⌘, KK), 3.44 (d,
J = 2.4 Hz, 2H, CH2C⌘, KE), 3.96 (s, 12H, OCH3, KK+KE), 4.34 (t, J = 7.4 Hz, 1H, CH, KK), 5.89 (br, 2H,
OH, KE), 5.94 (br, 2H, OH, KK), 6.70 (d, J = 15.4 Hz, 2H, CH=CH, KK), 6.91 (d, J = 8.0 Hz, 2H,H-5, KK),
6.95 (d, J = 8.0 Hz, 2H,H-5, KE), 6.99 (d, J = 15.4 Hz, 2H, CH=CH, KE), 7.04 (d, J = 2.0 Hz, 2H, H-2, KK),
7.07 (d, J = 2.0 Hz, 2H, H-2, KE), 7.12 (dd, J = 8.0 and 2.0 Hz, 2H, H-6, KK), 7.20 (dd, J = 8.0 and 2.0 Hz,
2H, H-6, KE), 7.66 (d, J = 15.4 Hz, 2H, CH=CH, KK), 7.73 (d, J = 15.4 Hz, 2H, CH=CH, KE).
3Z,5E-4-hydroxy-6-(4-hydroxy-3-methoxyphenyl)hexa-3,5-dien-2-one (11) [20].
In line with the general procedure, reaction of pentane-2,4-dione (1.00 g, 10.00 mmol) and vanillin
(1.37 g, 9.00 mmol) gave a crude product which was purified by FCC (PE/EtOAc 9.75:0.25), a↵ording
11 as a yellow solid (1.16 g), 55% yield, mp 144–146  C. 1H-NMR (CDCl3)   2.16 (s, 3H, CH3), 3.94 (s,
3H, OCH3), 5.40 (br, 1H, OH), 5.63 (s, 1H, CH), 6.33 (d, J = 16.0 Hz, 1H, CH=CH), 6.92 (d, J = 8.0 Hz,
1H, H-5), 7.02 (d, J = 1.8 Hz, 1H, H-2), 7.09 (dd, J = 8.0 and 1.8 Hz, 1H, H-6), 7.53 (d, J = 16.0 Hz, 1H,
CH=CH). The spectroscopic data of this intermediate are in good agreement with those reported in
the literature.
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General Procedure for the Synthesis of Azido Intermediates 9 and 10.
A mixture of the appropriate benzyl halide (1.00 mmol) and NaN3 (10.0 molar equiv) in DMF
(10.0 mL) was stirred at 60  C for 10 h. After cooling to rt the reaction mixture was poured into H2O
and extracted with Et2O (3 ⇥ 20.0 mL); the combined organic layers were washed with brine, dried
over Na2SO4 and concentrated to dryness. The desired azide was employed in the next synthetic step
without any further purification.
1-(azidomethyl)-4-fluorobenzene (9)
Following the general procedure and starting from 4-fluorobenzyl bromide (0.66 mL, 5.29 mmol)
and NaN3 (3.44 g, 52.90 mmol), the title compound 9 was obtained as a yellow oil, 50% yield. 1H NMR
(CDCl3)   4.29 (s, 2H, CH2 N3), 7.03–7.07 (m, 2H, Ar), 7.24–7.29 (m, 2H, Ar).
1-(azidomethyl)-4-methoxybenzene (10)
Following the general procedure and starting from 4-methoxybenzyl chloride (0.86 mL, 6.38 mmol)
and NaN3 (4.15 g, 63.80 mmol), the title compound 10 was obtained as a yellow oil, 67% yield. 1H
NMR (CDCl3)   3.82 (s, 3H, OCH3), 4.28 (s, 2H, CH2 N3), 6.92 (d, J = 8.4 Hz, 2H, Ar), 7.26 (d, J = 8.4 Hz,
2H, Ar).
4-(Prop-2-yn-1-yloxy)benzaldehyde (12) [46]
To a stirred suspension of 4-hydroxybenzaldehyde (1.00 g, 8.19 mmol) and anhydrous K2CO3
(1.36 g, 9.83 mmol) in acetone (100 mL), propargyl bromide solution (80 wt% in toluene, 1.09 mL,
9.83 mmol) was added dropwise. The reaction mixture was stirred under reflux for 8 h, monitoring
the reaction progress by TLC. The mixture was hot filtered, and the solvent was evaporated under
reduced pressure. The resulting crude product was purified by FCC (PE/EtOAc 4:1) to a↵ord 12 as a
pale yellow solid, 78% yield, mp 75 77  C. 1H-NMR (CDCl3)   2.81 (t, J = 2.4 Hz, 1H, ⌘CH), 4.96 (d,
J = 2.4 Hz, 2H, CH2C⌘), 7.10 (d, 2H, J = 7.6 Hz, Ar), 7.83 (d, 2H, J = 7.6 Hz, Ar), 9.90 (s, 1H, CHO).
The spectroscopic data of this intermediate are in good agreement with those reported in the literature.
(Z)-3-(1-hydroxyethylidene)hex-5-yn-2-one (7-KE); 3-(prop-2-yn-1-yl)pentane-2,4-dione (7-KK).
A stirred suspension of pentane-2,4-dione (2.59 mL, 25.17 mmol), propargyl bromide solution
(80 wt% in toluene, 1.87 mL, 16.86 mmol), K2CO3 (2.32 g, 16.86 mmol) in acetone (150 mL) was heated
at 80  C for 6 h, monitoring the reaction progress by TLC. The mixture was hot filtered, and the solvent
was evaporated under reduced pressure. The resulting crude was purified by FCC (PE/DCM 4:1) to
isolate the desired compound as 7-KE pure and as 1.7:1.0 mixture of 7-KK/KE tautomers (1.40 g), 60%
yield, mp 42–45  C. 7-KE: 1H NMR (CDCl3)   2.03 (t, J = 2.4 Hz, 1H, C⌘CH), 2.18 (s, 6H, CH3), 2.99 (d,
J = 2.4 Hz, 2H, CH2C⌘). 7-KK/KE: 1H NMR (CDCl3)   2.03 (t, J = 2.4 Hz, 2H, C⌘CH, KK+KE), 2.18 (s,
6H, CH3, KE), 2.26 (s, 6H, CH3, KK), 2.70 (dd, J = 2.8 and 7.2 Hz, 2H, CH2C⌘, KK), 2.99 (d, J = 2.4 Hz,
2H, CH2C⌘, KE), 3.86 (t, J = 7.2 Hz, 1H, CH).
4.2. Cell Cultures and Treatments
Human CCRF–CEM acute lymphoblastic leukemia T cells and Jurkat acute T leukemia cells were
purchased from ATCC (Manassas, VA, USA) and propagated in RPMI 1640 (ATCC), supplemented
with 10% heat-inactivated fetal bovine serum (FBS, Biochrome, a division of Harvard Bioscience, Inc.,
Holliston, MA, USA), 1% L-glutamine (Sigma-Aldrich, Saint Louis, MO, USA) and 1% penicillin/
streptomycin solution 100 U/mL (Sigma-Aldrich, Saint Louis, MO, USA). Cells were maintained at
37  C in a humidified atmosphere containing 5% CO2. For all experiments, to keep cells in their
logarithmic growth phase, they were seeded at a density of 0.25 ⇥ 106 cells/mL and treated with
increasing concentrations of the di↵erent compounds for di↵erent time points, depending on the assay.
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4.3. Analysis of Cell Viability
CCRF–CEM was treated with increasing concentrations of all compounds or the reference
compound curcumin for 24 and 48 h and analyzed with the Guava ViaCount Reagent (Merck KGaA,
Darmstadt, Germany), following the manufacturer instructions. Briefly, cells were diluted with the
reagent containing 7-AAD and incubated at room temperature in the dark for 5 min before been
recorded at the flow cytometer. Then, to confirm the solidity of these data, viability was also determined
by the eosin exclusion dye. Viable cells were counted using a Bürker chamber and light microscopy
(Nikon eclipse TS2, Amsterdam, Netherlands). The IC50 was calculated by interpolation from the
nonlinear dose–response curve.
Cell death analysis with or without specific inhibitors on Jurkat cells was performed as follow.
Briefly, cells were pretreated for 1 h with or without the pan-caspase inhibitor carbobenzoxy-valyl-
alanyl-aspartyl-[O-methyl]-fluoromethylketone (zVAD-fmk, 10 µM, Bachem, Bubendorf, Switzerland),
the RIPK1 inhibitor necrostatin-1 s (Nec1s, 10 µM, Abcam, Cambridge, UK), the inhibitor of ROS and
lipid peroxidation ferrostatin-1 (Fer-1, 1 µM, Sigma-Aldrich, St. Louis, MO, USA) or the iron chelator
deferoxamine (DFO, 10 µM, Sigma-Aldrich) to, respectively block apoptosis, necroptosis or ferroptosis.
Then, Jurkat were treated for 48 h with compound 1 6 µM and cell death was analyzed through the
fluorescent apoptosis/necrosis (FAN) assay [37] using the cell-impermeant fluorescent nuclear probe
Sytox Red (Thermo Fisher Scientific, Waltham, MA, USA). Fluorescence was measured on a Tecan
Spark® 20-M multimode microplate reader.
4.4. Analysis of Cell Cycle
After treatment with 1 for 24 h, cells were fixed with 70% ice-cold ethanol and, after washing,
suspended in 200 µL of Guava cell cycle reagent (Merck KGaA), containing propidium iodide. At the
end of incubation at room temperature for 30 min in the dark, samples were analyzed via flow cytometry.
4.5. Analysis of Cell Death
After 24 h treatments with 1, aliquots of 2 ⇥ 104 CCRF–CEM were resuspended in 100 µL of RPMI
1640 containing at least 10% of FBS and stained with an equal volume of Guava Nexin Reagent (Merck
KGaA) containing annexin V-phycoerythrin and 7-amino-actinomycin D (7-AAD) and analyzed via
flow cytometry.
4.6. Analysis of Mitochondrial Transmembrane Potential
The mitochondrial transmembrane potential was assessed using MitoProbeTM DilC1(5) Assay kit
(Molecular Probes, Thermo Fisher Scientific, Waltham, MA, USA). Briefly, after 24 h from compound
1 treatment, 106 cells were washed and treated with 50-nM DilC1(5) (1,10,3,3,30,30-hexamethylindo
dicarbocyanine iodide) for 20 min at 37  C, 5% CO2. Cells were washed with PBS 1X (Sigma-Aldrich) and
suspended for flow cytometric analysis in a solution composed of equal volumes of RPMI 1640 containing
at least 10% of FBS and Guava Nexin Reagent. CCCP (carbonyl cyanide 3-chlorophenylhydrazone) was
used as positive control.
4.7. Evaluation of Caspase-8 Activity
The activity of caspase-8 cells was assessed using the CaspGLOW Fluorescein Active Caspase
8 Staining Kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Briefly, after 24 h from
compound 1 treatment, 106 cells were washed and incubated for 30 min with the reagent. Cells were
washed again, stained with 7-AAD (BD Bioscience, Franklin Lakes, NJ, USA) for 1 h and read flow
cytometrically. Results were expressed as percentage of apoptotic cells with active caspase 8. Apoptotic
cells were identified thanks to the staining with 7-AAD (Supplementary Figure S7D) [47].
On note, compound 1 green autofluorescence was recorded during this assay, but did not affect the
analysis. Gating strategy and autofluorescence handling are showed in Figure S7, Supplementary Materials.
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4.8. Flow Cytometry
All procedures except for the analysis of caspase 8 activity were performed with a Guava EasyCyte
6HT-2 L (Merck KGaA) while for caspase 8 FACSCanto cytometer (Becton Dickinson, BD, San Jose, CA,
USA) was used. At least 10,000 events (cells) were recorded for each sample. In all cytofluorimetric
analyses, cell debris and clumps were gated out.
4.9. Statistical Analysis
All biologic experiments were performed at least in triplicates. All results are expressed as mean
± SEM. Di↵erences among treatments were evaluated by repeated ANOVA, followed by Bonferroni
or Dunnett as posttest, using GraphPad InStat version 6.00 (GraphPad Prism, San Diego, CA, USA).
p < 0.05 was considered significant.
4.10. Chemical Stability Study
The tested derivative 1 was dissolved in DMSO (0.50 mg/mL) and the pH of the solution was adjusted
to 7.4 using 50-mM phosphate. The obtained solutions were then maintained at room temperature and at
70  C (oven) for 48 h and analyzed by RP-HPLC under the conditions reported in the Section 2.2.8.
5. Conclusions
The obtained data reveal that derivative 1 activates both apoptosis signaling pathways, potentially
inducing an optimal activation of the apoptotic machinery. This peculiar property offers promises for
achieving an amplified anticancer potential. Further studies will be also necessary to draw a toxicological
profile of compound 1 in order to elaborate a risk/benefit analysis. Given the high tolerability and low
toxicity of curcumin in terms of selectivity for tumor cells and lack of toxicity in vivo [48–50], we expect
compound 1 to be not less. The complete pharmaco-toxicological profile will support assessing if this
compound could be regarded as suitable for its development as an effective anticancer therapeutics.
Follow-up studies will be devoted to deeply investigate the molecular mode of its cell death induction.
Moreover, an extensive structure–activity relationship (SAR) study is now ongoing focused at a rational
optimization of this lead structure. The outcomes of these efforts will be reported in due time.
Supplementary Materials: The following are available online, Figure S1. 1H NMR (CDCl3, 400 MHz) copy of
compound 1, Figure S2. 13C NMR copy of compound 1, Figure S3. 1H–1H COSY copy of compound 1. Figure S4.
1H–13C HSQC copy of compound 1, Figure S5. 2D NOESY copy of compound 1, Figure S6. Cell-death analysis of
Jurkat cells pretreated with zVAD-fmk, Nec1s, DFO or Fer-1 and then treated with compound 1 for 48 h, Figure
S7. Gating strategy (A, B, C, D) and green autofluorescence management (E) in caspase 8 analysis, Figure S8.
HPLC copy for compound 1; Table S1 and S2. Physicochemical properties prediction for compounds 1–6; Table S3.
PAINS filters for compounds 1–6.
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